| The Cleveland Clinic Foundation Patent applications |
| Patent application number | Title | Published |
|---|
| 20120136410 | SYSTEMS AND METHODS FOR NEUROMODULATION USING PRE-RECORDED WAVEFORMS - A method is provided for neuromodulation to treat stroke. One step of the method includes recording an input waveform from a first site in the nervous system in a source subject. The first site is healthy or at least partially functioning. Next, an output waveform is applied to a second site in the nervous system of a target subject suffering from the stoke. The second site is diseased due to the stroke. | 05-31-2012 |
| 20120116244 | POSTURAL STABILITY IN PATIENTS HAVING A NEURO-DEGENERATIVE DISEASE USING A COMPUTATIONAL MODELING APPROACH TO DEEP BRAIN STIMULATION PROGRAMMING - A system and method can provide for conducting a stimulation of anatomic regions to treat a neuromotor, neurocognitive or neuromotor and neurocognitive disorder, according to which stimulation, motor regions are stimulated, while creep of current to non-motor regions is minimized. Stimulation parameters can be selected based on at least one dual task test that involves cognitive and motor functions, wherein the motor function is postural stability. | 05-10-2012 |
| 20120116211 | Methods for identifying target stimulation regions associated with therapeutic and non-therapeutic clinical outcomes for neural stimulation - method for identifying and activating specific axonal pathways for achieving therapeutic benefits during a neural stimulation, such as deep brain stimulation. Clinical data, diffusion tensor tractography, and computer models of patient-specific neurostimulation may be used to identify particular axonal pathways activated by deep brain stimulation and to determine their correlations with specific clinical outcomes. | 05-10-2012 |
| 20120059400 | APPARATUS AND METHODS FOR OCCLUDING A HOLLOW ANATOMICAL STRUCTURE - A clamp having at least first and second elongate clamping portions adapted to be placed on opposite sides of the hollow anatomical structure. The first and second elongate clamping portions respectively include ends coupled together with respective resilient urging members configured to urge at least one of the first and second elongate clamping portions toward the other of the first and second elongate clamping portions from an open position into a clamping position to occlude the hollow anatomical structure. The clamp includes tissue ingrowth structure on the clamping portions. | 03-08-2012 |
| 20120041459 | METHOD AND APPARATUS FOR INCREASING BLOOD FLOW THROUGH AN OBSTRUCTED BLOOD VESSEL - A method of increasing blood flow through an obstructed blood vessel includes providing an expandable member substantially made of a mesh having a plurality of interstices. The expandable member is inserted into the blood vessel, positioned within the blood vessel with the proximal member end upstream of the distal member end and the member body located radially adjacent at least a portion of an obstruction, and expanded to bring at least a portion of the member body into contact with the obstruction. An outward radial force is exerted on the obstruction to dislodge at least one fragment from the obstruction and to enhance blood flow through the blood vessel past the obstruction. The at least one fragment is passed through at least one interstice of the member body in the radial direction, and is selectively retained within the expandable member. | 02-16-2012 |
| 20120017943 | METHODS AND DEVICES TO CLEAR OBSTRUCTIONS FROM MEDICAL TUBES - A device for clearing obstructions from a medical tube, such as a chest tube, is disclosed in various embodiments. The device features a clearance member in the form of a loop. The loop desirably has a diameter that substantially corresponds to the inner diameter of the medical tube. Also desirably, the loop presents a substantially unobstructed pathway therethrough for the flow of material from a location in the medical tube distal to the loop to a location in the medical tube proximal to the loop regardless whether the clearance member is being translated or is at rest in the medical tube. Methods of utilizing such a device are also disclosed. | 01-26-2012 |
| 20120010696 | THORACIC DEPLOYMENT DEVICE AND STENT GRAFT - A stent graft introducer for intraluminal deployment of a stent graft ( | 01-12-2012 |
| 20110307048 | PRE-LOADED MULTIPORT DELIVERY DEVICE - A pre-loaded stent graft delivery device and stent graft, the stent graft delivery device. The stent graft has at least one fenestration or side arm and the fenestration is preloaded with an indwelling guide wire. Indwelling access sheaths are provided within auxiliary lumens of a pusher catheter and dilators are preloaded into the access sheaths along with the indwelling guide wire. A handle assembly at a distal end of the guide wire catheter. The handle includes a multiport manifold with access ports to the auxiliary lumens in the pusher catheter. Upon deployment of the stent graft into the vasculature of a patient, the indwelling guide wire can be used to facilitate cathertisation of a side branch or target vessel through the fenestration or be used to stabilise the access sheath during catheterisation, advancement of the access sheath into the target vessel and deployment of a covered or uncovered stent therein through the access sheath. | 12-15-2011 |
| 20110306900 | GUIDEWIRE CONTROL DEVICE - A controller ( | 12-15-2011 |
| 20110305707 | COMPOSITIONS AND METHODS FOR TREATING CANCER - The present invention provides methods for treating cancer in a subject, as well as related compositions and kits that employ a therapeutic agent, or a nucleic acid sequence encoding a therapeutic agent, selected from apolipoprotein A-1 (ApoA1) or biologically active fragment, an ApoA1 mimetic, an agent that increases expression of ApoA1, or a binding agent specific for oxidized ApoA1. In certain embodiments, the ApoA1 or ApoA1 mimetic is at least partially oxidation resistant. | 12-15-2011 |
| 20110287449 | MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE - Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a predetermined value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from healthy controls. Such comparison characterizes the test subject's risk of developing CVD. | 11-24-2011 |
| 20110235892 | System and Method for Identifying a Vascular Border - A system and method is provided for using a first vascular image, or more particularly a plurality of control points located thereon, to identify a border on a second vascular image. Embodiments of the present invention operate in accordance with an intra-vascular ultrasound (IVUS) device and a computing device electrically connected thereto. Specifically, in one embodiment of the present invention, an IVUS console is electrically connected to a computing device and adapted to acquire IVUS data. The IVUS data (or multiple sets thereof) is then provided to (or acquired by) the computing device. In one embodiment of the present invention, the computing device includes a plurality of applications operating thereon—i.e., a border-detection application, an extrapolation application, and an active-contour application. These applications are used to (i) identify a border and control points on a first IVUS image (i.e., any IVUS image), (ii) extrapolate the control points to a second IVUS image (i.e., another IVUS image), (iii) identify a border on the second IVUS image, and (iv) adjust the border on the second IVUS image in accordance with at least one factor. In one embodiment of the present invention, the at least one factor is selected from a group consisting of gradient factor, continuity factor, and curvature factor. | 09-29-2011 |
| 20110201947 | OXIDIZED PARAOXONASE 1 AND PARAOXONASE 1/HDL PARTICLE NUMBER RATIO AS RISK MARKERS FOR CARDIOVASCULAR DISEASE - The present invention provides methods and markers for characterizing a subject's, particularly a human subject risk of having cardiovascular disease. The present invention also provides methods of characterizing a subject's risk of developing cardiovascular disease. In another embodiment, the present invention provides methods for characterizing a subject's risk of experiencing a complication of cardiovascular disease or major adverse cardiac event within 1, 3, or 10 years. In another embodiment, the present invention provides a method for determining whether a subject presenting with chest pain is at risk near term of experiencing a heart attack or other major adverse cardiac event. The present methods are especially useful for identifying those subjects who are in need of highly aggressive CVD therapies as well as those subjects who require no therapies targeted at inhibiting or preventing CVD or complications of CVD. | 08-18-2011 |
| 20110200689 | METHODS FOR TREATING GLIOBLASTOMA WITH HERBAL COMPOSITIONS - The inventive subject matter relates to methods for treating glioblastoma, comprising administration of a composition comprising therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger; and therapeutically effective amounts of hydroalcoholic extracts of holy basil, ginger, turmeric, | 08-18-2011 |
| 20110196253 | BRAIN STIMULATION MODELS, SYSTEMS, DEVICES, AND METHODS - This document discusses, among other things, brain stimulation models, systems, devices, and methods, such as for deep brain stimulation (DBS) or other electrical stimulation. In an example, a target volume of activation (VOA) can be received, a test VOA can be simulated, and at least one of a target electrode location or parameter can be provide using a relationship between the target VOA and the test VOA. | 08-11-2011 |
| 20110191275 | SYSTEM AND METHOD TO ESTIMATE REGION OF TISSUE ACTIVATION - A computer-implemented method for determining the volume of activation of neural tissue. In one embodiment, the method uses one or more parametric equations that define a volume of activation, wherein the parameters for the one or more parametric equations are given as a function of an input vector that includes stimulation parameters. After receiving input data that includes values for the stimulation parameters and defining the input vector using the input data, the input vector is applied to the function to obtain the parameters for the one or more parametric equations. The parametric equation is solved to obtain a calculated volume of activation. | 08-04-2011 |
| 20110184487 | REVERSING COGNITIVE-MOTOR IMPAIRMENTS IN PATIENTS HAVING A NEURO-DEGENERATIVE DISEASE USING A COMPUTATIONAL MODELING APPROACH TO DEEP BRAIN STIMULATION PROGRAMMING - A system and method may provide for conducting a stimulation of anatomic regions to treat a neuromotor, neurocognitive or neuromotor and neurocognitive disorder, according to which stimulation, motor regions are stimulated, while creep of current to non-motor regions is minimized. Stimulation parameters may be selected based on tests of motor function, tests of cognitive function, and tests of a combination of motor and cognitive functions. | 07-28-2011 |
| 20110165594 | SYSTEMIC MARKERS FOR ASTHMA AND ANALOGOUS DISEASES - Provided herein are diagnostic and prognostic methods, diagnostic and prognositic markers, and methods for evaluating anti-inflammatory agents or drugs in subjects with asthma and/or an analogous disease associated with high oxidative and nitrative stress at the disease site. In certain embodiments, the methods comprise a step of assaying for decreased levels of superoxide dismutase activity in the blood, serum, or plasma of the subject. In certain embodiments, the methods comprise a step of assaying for elevated levels of one or more oxidatively-modified SOD isoforms or species in the blood, serum or plasma of the subject. Also provided are diagnostic kits for use in the present invention. In certain embodiments, such kits comprise at least one binding reagent that specifically binds to at least one oxidatively-modified SOD species. | 07-07-2011 |
| 20110160776 | APPARATUS AND METHOD FOR BODY TISSUE FIXATION - A body tissue fixation apparatus includes a plate having oppositely disposed outer and tissue-contacting surfaces, and at least one fixation hole extending between the outer and tissue-contacting surfaces along a longitudinal axis. The fixation hole is defined in part by an inner hole surface having at least one serration. The plate is adapted for affixation to at least one body tissue member. At least one fixation device of the body tissue fixation apparatus has a shank and a head portion, the shank being insertable through the fixation hole in the plate to affix the plate to the body tissue member upon rotation of the head portion. At least one deformable member is connected to the head portion, the deformable member extending laterally in a direction substantially perpendicular to the longitudinal axis and being adapted to deflect to engage with at least one serration formed on the inner hole surface. Engagement between the deformable member and the serration helps to prevent displacement of the fixation device within the fixation hole. A method for using the body tissue fixation apparatus is also described. | 06-30-2011 |
| 20110152224 | MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE - Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a predetermined value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from healthy controls. Such comparison characterizes the test subject's risk of developing CVD. | 06-23-2011 |
| 20110135674 | Markers of XMRV Infection and Uses Thereof - The present invention relates generally to assays for the detection of Xenotropic Murine Leukemia Virus-related Retrovirus (“XMRV”) and diseases associated with XMRV infection. Additionally, the invention relates to specific XMRV antigens capable of inducing an immunogenic response as well as XMRV-related nucleic acids having significant diagnostic, screening, and therapeutic utilities. | 06-09-2011 |
| 20110104818 | CARBAMYLATED PROTEINS AND RISK OF CARDIOVASCULAR DISEASE - Methods for characterizing a test subject's, particularly a human test subject's, risk of having cardiovascular disease or developing cardiovascular disease are provided. Also provided are methods for characterizing a test subject's risk of experiencing a complication of cardiovascular disease near term. The methods comprise determining levels of one or more carbamylated biomarkers in a bodily fluid of the test subject and/or comparing these levels with a reference value. In certain embodiments, the carbamylated biomarkers are carbamylated albumin, carbamylated fibrinogen, carbamylated immunoglobulin and carbamylated apolipoprotein A. In other embodiments, particularly where the test subject does not have clinical evidence of renal disease, the carbamylated biomarker is free and/or total peptide-bound homocitrulline. | 05-05-2011 |
| 20110104694 | COMPOSITIONS AND METHODS FOR DETECTING CANCER - The present invention provides methods and compositions involving detecting the presence of and/or assessing the risk of cancer in a subject. These methods include methods of detecting and diagnosing cancer in an individual; methods of identifying individuals at risk of developing a cancer; and methods of staging a cancer. The methods generally involve detecting a palladin gene nucleotide sequence alteration that has been found to be associated with cancer and/or detecting a level of a palladin mRNA and/or protein in a biological sample. The present invention further provides nucleic acid probes, nucleic acid primers, and antibodies, as well as kits comprising one or more of the same, for use in a subject method. | 05-05-2011 |
| 20110082397 | SYSTEMS AND METHODS FOR IMPROVING MOTOR FUNCTION WITH ASSISTED EXERCISE - One embodiment of the present invention includes a system and method for alleviating symptoms of a medical disorder of a patient by forced exercise. The system includes an exercise machine having movable portions that move in response to a first contribution by a patient and in response a second contribution by a motor. The system further includes at least one mechanical sensor and a control system programmed to alter the second contribution by the motor in response to the sensed data. | 04-07-2011 |
| 20110066407 | Systems and methods for determining volume of activation for spinal cord and peripheral nerve stimulation - This document discloses, among other things, systems and methods for determining volume of activation for spinal cord stimulation (“SCS”) using a finite element model (FEM) circuit to determine a FEM of an implanted electrode and a spinal cord in which the electrode is implanted, a Fourier FEM solver circuit to calculate a potential distribution in the spinal cord using information from the FEM circuit and a capacitive component of at least one of the implanted electrode and the spinal cord, and a volume of activation (VOA) circuit to predict a VOA using the potential distribution and a neuron model. | 03-17-2011 |
| 20110040351 | SYSTEM AND METHOD TO DEFINE TARGET VOLUME FOR STIMULATION OF THE SPINAL CORD AND PERIPHERAL NERVES - One embodiment provides a computer-implemented method that includes storing a volume of tissue activation (VTA) data structure that is derived from analysis of a plurality of patients. Patient data is received for a given patient, the patient data representing an assessment of a patient condition. The VTA data structure is evaluated relative to the patient data to determine a target VTA for achieving a desired therapeutic effect for the given patient. | 02-17-2011 |
| 20110040286 | METHODS AND DEVICES TO CLEAR OBSTRUCTIONS FROM MEDICAL TUBES - A device for clearing obstructions from a medical tube, such as a chest tube, is disclosed in various embodiments. The device features a clearance member in the form of a loop. The loop desirably has a diameter that substantially corresponds to the inner diameter of the medical tube. Also desirably, the loop presents a substantially unobstructed pathway therethrough for the flow of material from a location in the medical tube distal to the loop to a location in the medical tube proximal to the loop regardless whether the clearance member is being translated or is at rest in the medical tube. Methods of utilizing such a device are also disclosed. | 02-17-2011 |
| 20110014603 | TARGETS FOR USE IN DIAGNOSIS, PROGNOSIS AND THERAPY OF CANCER - Provided herein are targets that can be used for the diagnosis, prognosis and therapy of a variety of cancers. | 01-20-2011 |
| 20100285517 | TRIMETHYLAMINE COMPOUNDS AS RISK PREDICTORS OF CARDIOVASCULAR DISEASE - Methods of characterizing a test subject's risk of having or developing cardiovascular disease are provided. The methods include using an analytic device to determine levels of choline-related trimethylamine-containing compounds such as trimethylamine N-oxide, choline, or betaine in a biological sample obtained from the subject and comparing the levels of the choline-related trimethylamine-containing compound in the subject's biological sample to a control value. The test subject's risk of having cardiovascular disease is then characterized as higher if the levels of the choline-related trimethylamine-containing compound are higher than the control value. Also provided are methods of identifying a subject at risk of experiencing a complication of atherosclerotic cardiovascular disease, and methods of evaluating the efficacy of a cardiovascular therapeutic agent in a subject with cardiovascular disease using levels of choline-related trimethylamine-containing compounds. | 11-11-2010 |
| 20100255009 | Methods for Inducing Mixed Donor-Recipient Chimerism in an Allograft Transplant Recipient - A method is provided for obtaining mixed donor-recipient chimeric cells, comprising the steps of (a) administering to an allograft recipient a short-term immunosuppressive regimen that depletes about 50% to about 99.9% of recipient T cells circulating in the peripheral blood of the recipient; (b) implanting an allograft from a donor into the recipient; (c) allowing the development of mixed donor-recipient chimeric cells in the recipient after completion of the immunosuppressive regimen; and (d) harvesting the chimeric cells from the recipient. The invention further provides method for compiling a library of chimeric cells and using the library to select of chimeric cells for the induction of tolerance to an allograft in a naïve or previously transplanted recipient. | 10-07-2010 |
| 20100196338 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE - A fusion protein for treating cardiovascular disease includes a transcription factor (TF) and a cell-penetrating peptide (CPP). The fusion protein can be expressed from a cell that is delivered to the tissue being treated. | 08-05-2010 |
| 20100185269 | CORPUS CALLOSUM NEUROMODULATION ASSEMBLY - Neuromodulation assemblies with lead bodies having curvatures that mimic the curvatures of the splenium, trunk, genu, or rostrum of the corpus callosum. Methods of stimulating the corpus callosum and methods of securing an electrical lead in the brain are also provided. | 07-22-2010 |
| 20100183607 | RISK MARKERS FOR CARDIOVASCULAR DISEASE - Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotein A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy. | 07-22-2010 |
| 20100183553 | Composition and Methods for Affecting Metallocorrinoid Uptake - The present invention is directed to compositions and methods for affecting metallocorrinoid uptake. The compositions and methods of the present invention are particularly useful in enhancing the uptake or availability of biologically active metallocorrinoids (e.g. cobalamin and its analogs). The present invention is particularly useful in the treatment or prevention of conditions that result from low expression or activity of proteins involved in the processing of metallocorrinoids, as well as in conditions which would benefit from enhanced uptake or availability of cobalamin or its biologically active analogs of cobalamin (e.g. cobalamin drug conjugates). | 07-22-2010 |
| 20100167316 | Enrichment of Tissue-Derived Adult Stem Cells Based on Retained Extracellular Matrix Material - Methods for enriching, detecting, or using adult stem cells through the use of recognition ligands that specifically bind to ECM components retained to the surfaces of adult stem cells are described. An ECM component such as hyaluronan that is retained to the surfaces of adult stem cells when removed from animal tissues can be used to detect a diverse population of adult stem cells based on the nature of the ECM niche region in which the adult stem cells normally reside. For example, a separation method such as magnetic separation can be used to detect and isolate or enrich adult stem cells based on a recognition ligand that is specific for an ECM component that is retained to the surfaces of adult stem cells to a greater degree than to other cells in the population. | 07-01-2010 |
| 20100159466 | TARGETS FOR USE IN DIAGNOSIS, PROGNOSIS AND THERAPY OF BREAST CANCER - The invention is directed to methods of diagnosing breast cancer, susceptibility to breast cancer, nodal metastasis of a breast cancer and screening for breast cancer in an individual in need thereof comprising detecting the presence of a loss of heterozygosity/allelic imbalance (LOH/AI) at one or more specific loci (markers) in the genome of the individual, wherein the presence of the LOH/AI at the one or more specific loci in the genome of the individual is indicative of a diagnosis of breast cancer in the individual. | 06-24-2010 |
| 20100150947 | TOLERANCE INDUCTION AND MAINTENANCE IN HEMATOPOIETIC STEM CELL ALLOGRAFTS - Provided are methods and compositions for the induction and maintenance of tolerance in hematopoietic stem cell allografts. | 06-17-2010 |
| 20100093052 | MAGNETIC CELL SEPARATION - Systems and methods are provided separating a first group of cells from a mixture of at least first and second groups of cells in a suspending fluid. The system includes an annular flow channel and at least one magnetic element positioned around the exterior of the annular flow channel as to provide a radially symmetric magnetic field around at least a portion of the annular flow channel. The at least one magnetic element is configured to provide a gradually increasing magnetic field along the axis of flow as to limit the maximum magnetic gradient within the annular flow channel. A pump is operatively connected to a terminal end of the annular flow channel to force the suspending fluid through the annular channel. | 04-15-2010 |
| 20100092961 | Methods and compositions for detection of Cowden Syndrome (CS) and CS-like syndrome - In one aspect, the invention is directed to a method of detecting Cowden syndrome (CS) or CS-like syndrome in an individual comprising detecting the presence of a mutated succinate dehydrogenase B (SDHB), mutated succinate dehydrogenase D (SDHD) or combination thereof in the individual, wherein detection of a mutated SDHB, SDHD or a combination thereof indicates that the individual is positive for CS or CS-like syndrome. In another aspect, the invention is directed to a method of determining whether an individual is at risk for developing Cowden syndrome (CS) or CS-like syndrome comprising detecting the presence of a mutated succinate dehydrogenase B (SDHB), mutated succinate dehydrogenase D (SDHD) or combination thereof in the individual, wherein detection of a mutated SDHB, SDHD or a combination thereof indicates that the individual is at risk for developing for CS or CS-like syndrome. In yet another aspect, the invention is directed to an article of manufacture for detecting Cowden syndrome (CS) or Cowden-like syndrome in an individual, comprising one or more agents that detects mutated succinate dehydrogenase B (SDHB), mutated succinate dehydrogenase D (SDHD) or combination thereof in the individual, and instructions for use. | 04-15-2010 |
| 20100082047 | APPARATUS AND METHODS FOR OCCLUDING A HOLLOW ANATOMICAL STRUCTURE - A device for occluding a hollow anatomical structure includes a clamp having at least first and second clamping portions adapted to be placed on opposite sides of the anatomical structure. At least one of the first and second clamping portions is movable toward the other from an open position to a clamping or closed position to occlude the anatomical structure. The clamp has an annular shape configured to surround the hollow anatomical structure in the open position and a flattened shape in the clamping position configured to occlude the hollow interior of the anatomical structure. The clamp is preferably covered with fabric to promote tissue ingrowth. A clamp delivery and actuation device is provided for allowing the clamp to be applied in either an open surgical procedure or a minimally invasive procedure. | 04-01-2010 |
| 20100074977 | Methods for treating glioblastoma with herbal compositions - The inventive subject matter relates to methods for treating glioblastoma, comprising administration of a composition comprising therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger; and therapeutically effective amounts of hydroalcoholic extracts of holy basil, ginger, turmeric, | 03-25-2010 |
| 20090274678 | Compositions and methods to treat urinary incontinence - A method is disclosed for treatment of urinary incontinence. The method includes the steps of providing to a person or animal, in the vicinity of a pubo-urethral ligament of the person or animal, a composition including collagen macromolecules that have hydroxyphenyl side groups substituted thereon, which are reacted to form dihydroxyphenyl linkages. In an embodiment, the collagen macromolecules are gelatin macromolecules. In another embodiment, the hydroxyphenyl side groups are tyramine side groups and the dihydroxyphenyl linkages are dityramine linkages. The composition can be injected into a space between a urethra and a pubis of the person or animal wherein the pubo-urethral ligament is disposed in the space. The method is advantageous, for example, based on being minimally invasive. | 11-05-2009 |
| 20090252700 | Hydroxyphenyl cross-linked macromolecular network and applications thereof - A synthetic nucleus pulposus is provided that is useful in treatment of degenerative disc disease, augmentation of a degenerate disc, and alleviation of back pain. In an embodiment the synthetic nucleus pulposus comprises hyaluronan macromolecules that have been cross-linked via dihydroxyphenyl linkages. The synthetic nucleus pulposus restores or improves the water-retention capability of the disc. A method of treating an intervertebral disc with the cross-linked hyaluronan macromolecules is also provided. A method of regenerative therapy to address loss of cells of nucleus pulposus of an intervertebral disc based on treatment with the cross-linked hyaluronan macromolecules and mesenchymal stem cells is also provided. | 10-08-2009 |
| 20090246833 | Small interfering RNAS as non-specific drugs - The present invention is directed to a method of modulating (e.g., inducing, inhibiting) activation of a double stranded RNA (dsRNA) signaling pathway, such as the dsRNA signaling pathway that accompanies RNA interference (RNAi) of a target RNA sequence, in a cell, comprising introducing into the cell small interfering RNA (siRNA) that degrades the target RNA sequence, and maintaining the cell under conditions in which RNAi of the target RNA sequence occurs and activation of the dsRNA signaling pathway is modulated in the cell. | 10-01-2009 |
| 20090240122 | INTRAJUGULAR CATHETER - A catheter for insertion into a vascular system of a patient and for directing fluid flow includes a catheter body having a longitudinal axis and longitudinally spaced proximal and distal catheter ends with an intermediate catheter portion defined therebetween. An intermediate catheter outlet in the catheter body is located in the intermediate catheter portion and is spaced longitudinally from the proximal and distal catheter ends. A first lumen is defined within the catheter body and has longitudinally spaced proximal and distal first lumen ends with a reversing bend located therebetween, the first lumen providing fluid communication between the proximal catheter end and the intermediate catheter outlet. The reversing bend is located longitudinally between the intermediate catheter outlet and the distal catheter end. The reversing bend directs fluid flow to turn approximately 180° as the fluid flows through the first lumen. A method of using the catheter is also described. | 09-24-2009 |
| 20090210208 | Brains stimulation models, systems, devices, and methods - This document discusses, among other things, brain stimulation models, systems, devices, and methods, such as for deep brain stimulation (DBS) or other electrical stimulation. In an example, a target volume of activation (VOA) can be received, a test VOA can be simulated, and at least one of a target electrode location or parameter can be provide using a relationship between the target VOA and the test VOA. | 08-20-2009 |
| 20090208992 | PARAOXONASE 1 ENZYMATIC ACTIVITY, A RISK INDICATOR FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS - Provided herein are methods for assessing the risk a subject or patient without significant evidence of cardiovascular disease has of experiencing a major adverse cardiac event or requiring revascularization near term. Also provided are methods of determining whether a subject who has experienced a major adverse cardiac event is at risk of experiencing a recurrent major adverse cardiac event near term. The present methods comprise determining the levels of paraoxonase 1 enzymatic activity in the blood, serum, plasma, or any combination of said bodily fluids in the subject. | 08-20-2009 |
| 20090204227 | Molecular enhancement of extracellular matrix and methods of use - A composition comprising a human- or animal-derived extracellular matrix and a macromolecular network which is prepared ex vivo is provided that is useful in the repair of a tissue injury, particularly in repair of tears or gaps between a tendon and a bone, such as in a rotator cuff tear. In an embodiment, the composition comprises a human- or animal-derived extracellular matrix having impregnated therein a macromolecular network of hyaluronan macromolecules that have been cross-linked via dihydroxyphenyl linkages, so that the cross-linked network is interlocked within the extracellular matrix. The resulting HA-incorporated extracellular matrix can be supplied in the form of a patch to reinforce a tissue repair or cover a tissue defect. | 08-13-2009 |
| 20090171411 | Method and System for Treating Acute Heart Failure by Neuromodulation - Methods and systems of treating acute heart failure by applying a therapy signal at least one sympathetic cardiopulmonary fiber surrounding the pulmonary trunk that affects heart contractility more than heart rate. Methods and systems also include adjusting the signal to effectuate treatment. | 07-02-2009 |
| 20090155243 | NON-HUMAN MODEL OF AUTOIMMUNE DISEASE - The invention is directed to a method of producing a non-human mammal having one or more pathological characteristics of retinal degeneration and/or age-related macular degeneration. In particular, the invention provides a method of producing a non-human mammal having age-related macular degeneration (AMD). The invention is also directed to non-human animals produced by the methods described herein. Methods of identifying an agent for use in inhibiting one or more pathological characteristics of retinal degeneration and/or AMD is also encompassed by the invention. Also provided is a method of treating AMD in an individual in need thereof comprising, administering to the individual an agent identified herein. | 06-18-2009 |
| 20090143766 | Hydroxyphenyl cross-linked macromolecular network and applications thereof - A dihydroxyphenyl cross-linked macromolecular network is provided that is useful in artificial tissue and tissue engineering applications, particularly to provide a synthetic macromolecular network for a wide variety of tissue types. In particular, artificial or synthetic cartilage, vocal cord material, vitreous material, soft tissue material and mitral valve material are described. In an embodiment, the network is composed of tyramine-substituted and cross-linked hyaluronan molecules, wherein cross-linking is achieved via peroxidase-mediated dityramine-linkages that can be performed in vivo. The dityramine bonds provide a stable, coherent hyaluronan-based hydrogel with desired physical properties. | 06-04-2009 |
| 20090142309 | Hydroxyphenyl cross-linked macromolecular network and applications thereof - A dihydroxyphenyl cross-linked macromolecular network is provided that is useful in artificial tissue and tissue engineering applications, particularly to provide a synthetic macromolecular network for a wide variety of tissue types. In particular, artificial or synthetic cartilage, vocal cord material, vitreous material, soft tissue material and mitral valve material are described. In an embodiment, the network is composed of tyramine-substituted and cross-linked hyaluronan molecules, wherein cross-linking is achieved via peroxidase-mediated dityramine-linkages that can be performed in vivo. The dityramine bonds provide a stable, coherent hyaluronan-based hydrogel with desired physical properties. | 06-04-2009 |
| 20090075830 | SYSTEM FOR IDENTIFYING AND ANALYZING EXPRESSION OF ARE-CONTAINING GENES - The present invention relates to a gene discovery system and gene expression systems specific for genes encoding ARE-containing mRNAs. In one aspect, the present invention relates to computational methods of selecting coding sequences of ARE-genes from databases using a one or more ARE search sequences. The ARE search sequences are from 10 to 80 nucleotides in length and comprise a sequence which is encompassed by one of the following two sequences: (a) WU/T(AU/TU/TU/TA)TWWW, SEQ ID NO. 1, wherein none or one of the nucleotides outside of the parenthesis is replaced by a different nucleotide, and wherein W represents A, U, or T; and (b) U/T(AU/TU/T/U/T)n, SEQ ID NO. 2 wherein n indicates that the search sequence comprises from 3 to 12 of the tetrameric sequences contained within the parenthesis. The method comprises extracting from the databases, those nucleic acids whose protein coding sequences are upstream and contiguous with a 3′ untranslated region (UTR) that comprises one of the ARE search sequences. The present invention also relates to methods of selectively amplifying RNA and cDNA molecules using primers derived from and complementary to the consensus 5′ sequence motifs and primers derived from and complementary to the ARE search sequence. The present invention also relates to methods of selectively amplifying ARE genes which employ a 3′ primer which is from 15 to 50 nucleotides and length and comprises from 2 to 10 pentamers having the sequence TAAAT. The pentameric sequences in the primers are either overlapping or non-overlapping. The 3′ primers are used in the reverse transcription step of the methods, the polymerase chain reaction (PCR) amplification step of the methods, or in both the reverse transcription step and the PCR amplification step of the methods. The present invention also relates to methods of making libraries which comprise portions of the ARE genes that are selectively amplified by the present methods and to methods of making microarrays which comprise probes that hybridize under stringent conditions to portions of the protein coding sequences of the ARE genes that are selectively amplified by the present methods. The present invention also relates to libraries and the microarrays that are made by such methods. | 03-19-2009 |
| 20090069703 | SYSTEM FOR ARTIFACT DETECTION AND ELIMINATION IN AN ELECTROCARDIOGRAM SIGNAL RECORDED FROM A PATIENT MONITOR - A system eliminates artifacts from an electrocardiogram signal. The system includes a monitor for receiving an electrocardiogram signal from a patient and a microprocessor utilizing a shift-invariant wavelet transform for decomposing the electrocardiogram signal into a plurality of scales. The microprocessor applies rules to the scales for removing artifacts from the scales. The microprocessor reassembles the plurality of scales to produce a reconstructed and accurate electrocardiogram signal without the artifacts. | 03-12-2009 |
| 20090061472 | ASSESSING THE RISK OF A MAJOR ADVERSE CARDIAC EVENT IN PATIENTS WITH CHEST PAIN - Methods for characterizing the near term risk of experiencing a major adverse cardiac event in a patient presenting with chest pain are provided. In one embodiment the method comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the patient. In another embodiment, the method comprises determining the level of MPO mass in a bodily sample obtained from the patient. In another embodiment, the method comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the patient. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, chlorotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation product. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a control value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from control population. Such comparison can also be used to determine the near term treatment of the patient. | 03-05-2009 |
| 20090043377 | Branched Vessel Endoluminal Device - An endoluminal prosthesis comprises a prosthetic trunk having a trunk lumen and a trunk wall, a first prosthetic branch having a first branch lumen and a branch wall, and a second prosthetic branch having a second branch lumen. The first branch lumen and the second branch lumen are both in fluid communication with the trunk lumen through the trunk wall and the second branch lumen is in fluid communication with the first branch lumen through the branch wall. Additional devices, systems, and methods are disclosed. | 02-12-2009 |
| 20090042294 | Hydroxyphenyl cross-linked macromolecular network and applications thereof - A dihydroxyphenyl cross-linked macromolecular network is provided that is useful in artificial tissue and tissue engineering applications, particularly to provide a synthetic macromolecular network for a wide variety of tissue types. In particular, artificial or synthetic cartilage, vocal cord material, vitreous material, soft tissue material and mitral valve material are described. In an embodiment, the network is composed of tyramine-substituted and cross-linked hyaluronan molecules, wherein cross-linking is achieved via peroxidase-mediated dityramine-linkages that can be performed in vivo. The dityramine bonds provide a stable, coherent hyaluronan-based hydrogel with desired physical properties. | 02-12-2009 |
| 20090035874 | THERAPEUTIC AGENTS AND METHODS FOR CARDIOVASCULAR DISEASE - The present invention provides methods and agents for treating subjects who have or are at risk of developing or having cardiovascular disease. Such agents inhibit binding of myeloperoxidase (MPO) to a molecule comprising the MPO binding site of apolipoprotein A-1 (apoA-1) and include a peptide fragment of apoA-1 comprising at least 4 contiguous amino acids in SEQ ID. NO: 2, a modified form of the apo-1 fragment comprising one or more D amino acids, a retro-inverso form of the apoA-1 peptide fragment, an organo-mimetic of the apoA-1 peptide fragment, a peptide-mimetic of the apoA1 peptide fragment, or a nucleic acid encoding the apo A-1 peptide fragment. The present invention also provides methods of identifying or screening test agents for treating subjects having or at risk of having or developing CVD. The method comprises incubating one or more test agents and MPO with a molecule comprising the MPO binding site of apoA-1 under conditions which permit binding of MPO to the MPO binding site and determining whether one or more of the agents inhibit such binding. | 02-05-2009 |
| 20090028823 | Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases - In one embodiment, a therapeutic composition containing a pentavalent antimonial is provided. The pentavalent antimonial can be sodium stibogluconate, levamisole, ketoconazole, and pentamidine and biological equivalents of said compounds. Additionally, pentavalent antimonials that can be used in accordance with the present invention may be any such compounds which are anti-leishmaniasis agents. The therapeutic composition of this embodiment contains an effective amount of pentavalent antimonial that can be used in treating infectious diseases. The types of diseases that can be treated with the present invention include, but are not limited to, the following: diseases associated with PTPase activity, immune deficiency, cancer, infections (such as viral infections), hepatitis B, and hepatitis C. The types of cancers that the present embodiment can be used to treat include those such as lymphoma, multiple myeloma, leukemia, melanoma, prostate cancer, breast cancer, renal cancer, bladder cancer. The therapeutic composition enhances cytokine activity. The therapeutic composition may include a cytokine, such as interferon α, interferon β, interferon γ, or granulocyte/macrophage colony stimulating factor. | 01-29-2009 |
| 20080301822 | Role of alpha1-adrenergic receptors - The present invention is directed to a transgenic non-human mammal (e.g., a rodent such as a mouse) whose genome comprises a recombinant nucleic acid sequence comprising an α | 12-04-2008 |
| 20080288018 | METHODS OF IMPROVING NEUROPSYCHOLOGICAL FUNCTION IN PATIENTS WITH NEUROCOGNITIVE DISORDERS - The present invention provides methods of improving neuropsychological function in a patient having a neurocognitive disorder by chemical or electrically modulating a target site(s) in the ventral striatum/ventral capsule region. Methods also include modulating the treatment based on a closed-loop feedback system that measures bodily activities associated with the neuropsychological function (i.e. that help to determine whether a neuropsychological function is or can be improved. | 11-20-2008 |
| 20080255632 | Modulation of the Pain Circuitry to Affect Chronic Pain - The present invention relates to methods of affecting chronic pain by applying an electrical and/or chemical signal to the target site of the pain circuitry associated with chronic pain. Such target sites include cerebral and deep brain target sites. | 10-16-2008 |
| 20080215101 | SYSTEMS AND METHODS FOR TREATING MEDICAL CONDITIONS BY STIMULATION OF MEDIAL THALAMIC REGION - A system for treating medical conditions by neuromodulation of one or more target sites in the nervous system. In certain embodiments, at least one of the target sites is the medial thalamic region, including the intralaminar nucleus and the adjacent white and grey matter. In certain embodiments, where there is more than one target site, the other target sites is elsewhere in the nervous system, including the globus pallidus interna, subthalamic nucleus, corpus callosum, cerebellum, cerebral cortex (including the premotor cortex, motor cortex, and sensory cortex), ventral striatum, lateral thalamus, substantia nigra, and pedunculopontine nuclei. The medical conditions include movement disorders or improvement of movement function, stroke, neuropsychiatric or neuropsychologic disorders, neurodevelopmental disorders, and pain. Methods for treating medical conditions by neuromodulation of the intralaminar nuclei either alone or in combination with another target site(s) is also provided. | 09-04-2008 |
| 20080208284 | SYSTEMS AND METHODS FOR NEUROMODULATION USING PRE-RECORDED WAVEFORMS - Methods for neuromodulation using waveform signals. In certain embodiments, an input waveform is obtained from a signal source site in a source subject and an output waveform is applied to a target site in a target subject. The source subject is a human or animal and the signal source site is in the nervous system, including the brain. The source subject and target subject are the same subjects or different subjects. The output waveform is identical to the input waveform or derived from the input waveform. In some embodiments, the output waveform is modified in response to physiologic feedback. Also provided are systems for neuromodulation using waveform signals. | 08-28-2008 |
